Company news
Vyome Holdings, Inc. (NASDAQ:HIND) news
Every Vyome Holdings, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer
September 14, 2026
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
May 28, 2026
Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity
May 12, 2026
Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026
April 22, 2026
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
April 6, 2026
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
March 26, 2026
Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company
February 24, 2026
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
February 18, 2026
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
February 11, 2026
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
February 2, 2026
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company
December 22, 2025
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval
December 8, 2025
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program
November 25, 2025
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
November 18, 2025
Vyome Holdings Announces Results of Annual Shareholder Meeting
November 4, 2025
Vyome Holdings Acquires MIT AI Spinout Oculo Health
September 29, 2025
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity
September 17, 2025
Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies
September 9, 2025
Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on M...
September 4, 2025
Vyome Signs MoU with Embryyo, India’s Leading Medical Device Innovation Studio
August 21, 2025
Vyome Announces Strategic Review of Livechain (OTCID: LICH)
August 18, 2025
Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell
August 15, 2025
Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow
August 14, 2025
Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND
August 13, 2025
Vyome Announces New Board of Directors with Deep MIT and AI Ties
August 12, 2025